Home › NCT07525635

Aspirin Dosing in Pregnancy

Aspirin Dosing and Platelet Phenotype in Pregnancy

Who can join

Ages 18 to 50 · Women

Inclusion Criteria:

* Pregnant people prior to 17 weeks
* Prenatal care at NYU Langone Health Obstetrics and Gynecology Associates
* Age 18-50 years
* Singleton viable gestation
* Pregnant patients at high risk of preeclampsia: Patients meeting USPSTF recommendation for aspirin prophylaxis for preeclampsia based on clinical risk factors.

Exclusion Criteria:

* Undergoing glucose challenge test (GCT) at time of blood draw
* Allergy or intolerance to aspirin
* Antithrombotic or antiplatelet therapy
* Anemia (hemoglobin \<10 g/dl) or thrombocytopenia (platelet count \<100,000), or thrombocytosis (platelet count \>600,000)
* Known hemorrhagic diathesis
* Planned delivery outside of NYU

About the study

The purpose of this study is assess platelet phenotypes based on aspirin dosing in pregnant patients at risk for the development preeclampsia who are taking 81mg twice a day aspirin. Blood samples will be collected approximately 4 weeks after initiation of aspirin to evaluate the platelet phenotype during pregnancy in patients.

What is being tested

• Aspirin (drug)

Sponsor: NYU Langone Health · Participants: 30 · Started: Apr 27, 2026

Contact the study team

• Christina A. Penfield, MD, MPH · Phone: 646-754-2700
• Lucia Muzzarelli · Phone: 646-754-2760

Official record on ClinicalTrials.gov — NCT07525635

Locations in the U.S.

From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.